216 related articles for article (PubMed ID: 32537431)
1. Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck.
Crombet Ramos T; Mestre Fernández B; Mazorra Herrera Z; Iznaga Escobar NE
Front Oncol; 2020; 10():817. PubMed ID: 32537431
[TBL] [Abstract][Full Text] [Related]
2. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Thai Hoa NT; Quang Huy H
Cureus; 2020 May; 12(5):e8105. PubMed ID: 32426197
[TBL] [Abstract][Full Text] [Related]
3. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.
Mazorra Z; Lavastida A; Concha-Benavente F; Valdés A; Srivastava RM; García-Bates TM; Hechavarría E; González Z; González A; Lugiollo M; Cuevas I; Frómeta C; Mestre BF; Barroso MC; Crombet T; Ferris RL
Front Pharmacol; 2017; 8():382. PubMed ID: 28674498
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.
Rodríguez MO; Rivero TC; del Castillo Bahi R; Muchuli CR; Bilbao MA; Vinageras EN; Alert J; Galainena JJ; Rodríguez E; Gracias E; Mulén B; Wilkinson B; de Armas EL; Pérez K; Pineda I; Frómeta M; Leonard I; Mullens V; Viada C; Luaces P; Torres O; Iznaga N; Crombet T
Cancer Biol Ther; 2010 Mar; 9(5):343-9. PubMed ID: 20448462
[TBL] [Abstract][Full Text] [Related]
6. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
[TBL] [Abstract][Full Text] [Related]
7. Combining Nimotuzumab With Chemotherapy for Patients With Locally Advanced and Intermediate-Stage Nasopharyngeal Cancer: A Retrospective Comparison Study Using Five-Year, Real-World Survival Data.
Rachman A; Sari SR; Munandar A; Adham M; Hutajulu SH
Cureus; 2023 Nov; 15(11):e48804. PubMed ID: 38098929
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Ang MK; Montoya JE; Tharavichitkul E; Lim C; Tan T; Wang LY; Wee J; Soong YL; Fong KW; Ng QS; Tan DS; Toh CK; Tan EH; Lim WT
Head Neck; 2021 May; 43(5):1641-1651. PubMed ID: 33547683
[TBL] [Abstract][Full Text] [Related]
9. Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials.
Guan M; Zhang D; Zhao Y; Mao M; Shen K; Wang X; Bi C
Front Oncol; 2024; 14():1380428. PubMed ID: 38939342
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F; Gracias E; Villena N; Cruz T; Corominas JM; Corradino I; Cedeño M; Campas C; Osorio M; Iznaga N; Bellosillo B; Rovira A; Marsoni S; Gascon P; Serrano S; Sessa C; Crombet T; Albanell J
Clin Cancer Res; 2010 Apr; 16(8):2474-82. PubMed ID: 20371675
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study.
Kumar A; Chakravarty N; Bhatnagar S; Chowdhary GS
South Asian J Cancer; 2019; 8(2):108-111. PubMed ID: 31069191
[TBL] [Abstract][Full Text] [Related]
12. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR.
Basavaraj C; Sierra P; Shivu J; Melarkode R; Montero E; Nair P
Cancer Biol Ther; 2010 Oct; 10(7):673-81. PubMed ID: 20647773
[TBL] [Abstract][Full Text] [Related]
13. Nimotuzumab plus chemotherapy with docetaxel, cisplatin, 5-fluorouracil for locally advanced head and neck squamous cell carcinoma: A clinical study.
Wang X; Gu J; Shao C; Han K; Meng J
J Cancer Res Ther; 2019; 15(2):312-316. PubMed ID: 30964103
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience.
Rawat S; Tandan H; Patel S; Chaudhari S
South Asian J Cancer; 2019; 8(1):52-56. PubMed ID: 30766856
[TBL] [Abstract][Full Text] [Related]
15. Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer.
Srinivas KS; Sundaram R; Divyambika CV; Chaudhari S
South Asian J Cancer; 2020; 9(1):43-46. PubMed ID: 31956621
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Yamamoto N; Harada H; Okamoto I; Masuda N; Hayakawa K; Satouchi M; Soejima T; Nishio M; Kozuka T; Takeda K; Tanaka M; Seto T; Sasaki T; Tsubouchi H; Kakurai Y; Nishimura Y; Nakagawa K
Clin Lung Cancer; 2021 Mar; 22(2):134-141. PubMed ID: 33518480
[TBL] [Abstract][Full Text] [Related]
19. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
20. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.
Liang J; E M; Wu G; Zhao L; Li X; Xiu X; Li N; Chen B; Hui Z; Lv J; Fang H; Tang Y; Bi N; Wang W; Zhai Y; Li T; Chen D; Zou S; Lu N; Perez-Rodríguez R; Zheng J; Wang L
Onco Targets Ther; 2013; 6():1589-96. PubMed ID: 24235844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
